Index to Volume 4

Author Index

A

Acchiardo SR: *see* Skoutakis VA et al, 392
Adams SC: *see* Newell GR et al, 284
Ahrens RC, Smith GD: Albuterol: an adrenergic agent for use in the treatment of asthma, 105
Allen LM: Commentary on etoposide, 71
Aselton P, Jick H, Habakangas JAS: Benzodiazpeine-related convulsions (letter), 164
Aviado DM, Porter JM: Pentoxifylline: a new drug for the treatment of intermittent claudication, 297

B

Barkaszi BA: *see* Forbes JA et al, 221
Barkaszi BA: *see* Forbes JA et al, 385
Barr WH: The once-daily theophylline controversy (editorial), 167
Barreuther A: Commentary on albuterol, 120
Barriere SL: Commentary on cefonicid, 332
Bartle WR: Commentary on bentiromide, 80
Bernstein IL: *see* C. S. T. Tse, 334
Bhattacharya A: *see* Khanderia U, 144
Boike SC: Commentary on amoxicillin/potassium clavulanate, 134
Bottini PB: *see* Devane JG, 230
Brown DC: *see* Lake KD et al, 161
Browne TR: Review of: Antiepileptic Drugs, second edition, 43
Burnakis TG: Surgical antimicrobial prophylaxis: principles and guidelines, 248
Bussey HI, Talbert RL: Promising uses of calcium-channel blocking agents, 137

C

Carter CA: *see* Skoutakis VA et al, 179
Carter CA: *see* Skoutakis VA et al, 392
Cersosimo RJ: Commentary on etoposide, 72
Coffman JD: Commentary on pentoxifylline, 306
Cohn JB, Wilcox CS: Long-term comparison of alprazolam, lorazepam and placebo in patients with an anxiety disorder, 93
Collins AJ: *see* Matzke GR et al, 158
Creaven PJ: Commentary on etoposide, 72
Crom WR, Evans WE: Review of: Biopharmaceutics and Clinical Pharmacokinetics, third edition, 232
Cunha BA: Commentary on ceftizoxime, 59

D

Dasta JF, Leier CV: Commentary on pirbuterol hydrochloride, 10
Devane JG, Bottini PB: Safety of Indos (letter), 230
DiPiro JT: Commentary on amoxicillin/potassium clavulanate, 135
Donn KH, Eshelman FN, Plachetka JR, Fabre L, Powell JR: The effects of antacid and propantheline on the absorption of oral ranitidine, 89

E

Echols RM: Commentary on cefonicid, 331, commentary on ceftizxome, 58
Ereshefsky L: Commentary on buspirone, 322
Erman M: *see* Rush AJ et al, 40
Eshelman FN: *see* Donn KH et al, 89
Evans WE: *see* Crom WR, 232

F

Fabre L: *see* Donn KH et al, 89
Fairchild C: *see* Rush AJ, 40
Fannin LD: Review of: Drugs and Drug Abuse, 44
Ferguson RK: Review of: Drug Treatment of Heart Failure, 165
Ferguson RK: *see* Vlasses PH et al, 272
Foldes FF: Commentary on vecuronium, 246
Forbes JA, Barkaszi BA, Ragland RN, Hankle JJ: Analgesic effect of acetaminophen, phenyltoloxamine and their combination in postoperative oral surgery pain, 221
Forbes JA, Barkaszi BA, Ragland RN, Hankle JJ: Analgesic effect of fendosal, ibuprofen and aspirin in postoperative oral surgery pain, 385
Foster TS: *see* Rapp RP et al, 211
Fraser DG: Review of: AMA Drug Evaluations, fifth edition, 44
Fraser DG: Review of: USAN and the USP Dictionary of Drug Names, 1984 edition, 45

G

Gelenberg AJ: Commentary on bupropion hydrochloride, 33
Gleckman RA: Review of: Antimicrobial Prescribing, second edition, 232
Gleckman RA, Roth RM: Community-acquired bacterial pneumonia in the elderly, 81
Goldberg HL: Buspirone hydrochloride: a unique new anxiolytic agent, 315

H

Habakangas JAS: *see* Aselton P et al, 164
Halstenson CE: *see* Matzke GR, 158
Hankle JJ: *see* Forbes JA et al, 216
Hankle JJ: *see* Forbes JA et al, 385
Hansten PD: Review of: Handbook of Clinical Pharmacology, second edition, 104
Henry JC: *see* Smith EB, 199
Hersh EM: *see* Newell GR et al, 284
Holt RJ: Fluphenazine decanoate-induced cholestatic jaundice and thrombocytopenia, 227
Hopkins CC: Commentary on cefonicid, 332
Hopkins CC: Commentary on ceftizoxime, 59
Hunt-Fugate AK, Zander J, Lesar TS: Adverse reactions due to dopamine blockade by amoxapine, 35
Hunter JR: *see* Porter JB et al, 381

I

Irvin JD: *see* Vlasses PH et al, 272

J

Jain AK, Michael R, Ryan JR, McMahon FG: Antihypertensive and biochemical effects of indacrinone enantiomers, 278
Jenne JW: Commentary on pirbuterol hydrochloride, 10
Jick H: *see* Aselton P et al, 164
Jick H: *see* Porter JB et al, 381
Jick H, Madsen S, Nudelman PM, Perera DR, Stergachis A: Postmarketing follow-up at Group Health Cooperative of Puget Sound, 99
Johnson CL: *see* VLasses PH et al, 272

K

Karim A: Commentary on article by Weinberger M pertaining to Theo-24 (Searle), 192
Katz RL: Commentary on vecuronium, 247
Kaye D: *see* Pontzer RE, 325
Khanderia U, Bhattacharya A: Acute intermittent porphyria: pathophysiology and treatment, 144
Kostis JB, Weinstein J: Commentary on piretanide, 178
Koup JR: Review of: Applied Clinical Pharmacokinetics, 43

L

Lake KD, Brown DC, Peterson CD: Digoxin toxicity: enhanced systemic elimination during oral activated charcoal therapy, 161
Larijani GE: *see* Vlasses PH, 179
Leier CV: *see* Dasta JF et al, 10
Lesar TS: *see* Hunt-Fugate AK, 35
Linfors EW: commentary on piretanide, 178
Lofdahl CG, Svedmyr K, Svedmyr N: Selectivity of bevantolol hydrochloride, a beta-1 adrenoceptor antagonist, in asthmatic patients, 205
Luckham DR: *see* Matzke GR et al, 158
Lydiard RB: Commentary on buspirone, 322

M

Maddox RR: Review of: Biopharmaceutics and Drug Interactions, third edition, 102
Madsen S: *see* Jick H et al, 99
Mansell PWA: *see* Newell GR et al, 284
Marsh JD, Smith TW: Piretanide: a loop-active diuretic, 170
Mattea EJ: Commentary on pentoxifylline, 307
Matzke GR, Luckham DR, Collins AJ, Halstenson CE: Effect of ticarcillin on gentamicin and tobramycin pharmacokinetics in a patient with end-stage renal disease, 158
Mayer KH: Inhalation-induced immunosuppression (editorial), 235
Mazzullo JM: Review of: The acquired immune deficiency syndrome (AIDS) and infections of homosexual men, 233
Michael R: *see* Jain AK et al, 278
Milavetz G, Weinberger M, Vaughan L: Dose dependency for absorption and elimination rates of theophylline, 216
Miller RD: Vecuronium: a new nondepolarizing neuromuscular-blocking agent, 238
Miller RR: Disclosure of conflicts of interest (editorial), 169
Miller RR: Changes in the masthead (editorial), 237
Miller RR: The review process (editorial), 295
Miller WA: *see* Trammel HL, 101
Mitchell CJ: Commentary on bentiromide, 79
Mullen PB: Review of: Pharmacological and Chemical Synonyms, seventh edition, 46

N

Nelson HS: *see* Weber RW et al, 1
Nelson HS, Weber RW: Commentary on albuterol, 121
Neu HC: Commentary on amoxicillin/potassium clavulanate, 133
Neu HC: Ceftizoxime: a beta-lactamase stable, broad-spectrum cephalosporin, 47
Newell GR, Adams SC, Mansell PWA, Hersh EM: Toxicity, immunosuppressive effects and carcinogenic potential of volatile nitrites: possible relationship to Kaposís sarcoma, 284
Nudelman PM: *see* Jick H et al, 99

O

O'Neal W: *see* Rapp RP et al, 211
Othmer SC: *see* Preskorn SH et al, 20

P

Perera DR: *see* Porter JB et al, 381
Peterson CD: *see* Lake KD et al, 161
Plachetka JR: *see* Donn KH et al, 89
Pontzer RE, Kaye D: Cefonicid: a long-acting, second-generation cephalosporin, 325
Porter JB, Jick H, Perera DR, Ylvisaker JT, Hunter JR: Long-term follow-up study of cimetidine, 381
Porter JM: *see* Aviado DM, 297
Powell JR: *see* Donn KH et al, 89
Preskorn SH, Othmer SC: Evaluation of bupropion hydrochloride: the first of a new class of atypical antidepressants, 20
Puglsey JA: Review of: Handbook of Clinical Drug Data, fifth edition, 103

Q

Quintiliani R: Commentary on cefonicid, 333
Quintiliani R: Evaluation of ceftizoxime, 59

R

Ragland RN: *see* Forbes JA et al, 221
Ragland RN: *see* Forbes JA et al, 385
Rapp RP, Young B, Foster TS, Tibbs PA, O'Neal W: Ceftazidime versus tobramycin/ticarcillin in treating hospital acquired pneumonia and bacteremia, 211
Rihn TL: Commentary on pentoxifylline, 307
Rogers AG: Book review, 292
Ronald AR: Commentary on amoxicillin/potassium clavulanate, 135
Rosow CE: Sufentanil citrate: a new opioid analgesic for use in anesthesia, 11
Roth RM: *see* Gleckman RA, 81
Rotmensch HH: *see* Vlasses PH, 272
Rubin RH: *see* Weber DJ et al, 122
Rush AJ, Schlesser MA, Erman M, Fairchild C: Alprazolam in bipolar-I depressions, 40
Ryan JR: *see* Jain AK et al, 278
Ryan PB: Book review, 293

S

Savarese JJ: Commentary on vecuronium, 245
Schentag JJ, Simons GW, Schultz RW, Vance JW, Williams JS: Complexation versus hemodialysis to reduce elevated aminoglycoside serum concentrations, 374
Schlesser MA: *see* Rush AJ et al, 40
Schultz RW: *see* Schentag JJ et al, 374
Sebel PS: Commentary on sufentanil citrate, 19
Shackleford RW: *see* Turner RA et al, 151
Shillcutt SD: Commentary on bupropion hydrochloride, 32
Shopsin B: Commentary on bupropion hydrochloride, 34
Simons GW: *see* Schentag JJ et al, 374
Sinkule JA: Etoposide: a semisynthetic epipodophyllotoxin, 61
Skolnick P, Paul SM, Weissman BA: Preclinical pharmacology of buspirone hydrochloride, 308
Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA: Liquid and solid potassium chloride: bioavailability and safety, 392
Skoutakis VA, Wojciechowski NJ, Carter CA: Commentary on piretanide, 179
Smith EB, Henry JC: Ketoconazole: an orally effective antifungal agent, 199
Smith GD: *see* Ahrens RC, 105
Smith RE: Commentary on ketoconazole, 203
Smith TW: *see* Marsh JD, 170
Stanley TH: Commentary on sufentanil citrate, 18
Stein ZLG: Commentary on vecuronium, 246
Stergachis A: *see* Jick H et al, 99
Svedmyr K: *see* Lofdahl CG et al, 205
Swanson BN: *see* Vlasses PH et al, 272

T

Talbert RL: *see* Bussey HI, 137
Tibbs PA: *see* Rapp RP et al, 211
Tolkoff-Rubin NE: *see* Weber DJ et al, 122
Toskes PP: The bentiromide test for pancreatic exocrine insufficiency, 74
Trammel HL, Miller WA: Review of: Core Journals in Clinical Pharmacology, 101
Tse CST, Bernstein IL: Corticosteroid aerosols in the treatment of asthma, 334
Turner RA, Whipple JP, Shackleford RW: Diflunisal 500-750 mg versus aspirin 2600-3900 mg in the treatment of rheumatoid arthritis, 151

V

Van Tyle JH: Ketoconazole, 343
Vance JW: *see* Schentag JJ, 374
Vaughan L: *see* Milavetz G et al, 216
Vlasses PH, Rotmensch HH, Swanson BN et al: Indacrinone: natriuretic and uricosuric effects of various ratios of its enantiomers in healthy men, 272
Vlasses PH, Larijani GE: Commentary on piretanide, 179

W

Waller ES: Safety of Indos (letter), 230
Weber DJ, Tolkoff-Rubin NE, Rubin RH: Amoxillin and potassium clavulanate: an antibiotic combination, 122
Weber RW: *see* Nelson HS, 121
Weber RW, Nelson HS: Pirbuterol hydrochloride: evaluation of beta adrenergic agonist activity in reversible obstructive pulmonary disease and congestive heart failure, 1
Weinberger M: *see* Milavetz G et al, 216
Weinberger MM: Theophylline QID, TID, BID and now QD?, 181
Weiner B: Book review, 292
Weinstein J: *see* Kostis JB, 178
Weissman BA: *see* Skolnick P et al, 308
Wells BG: Commentary on buspirone, 323
West DP: Commentary on ketoconazole, 204
Whipple JP: *see* Turner RA et al, 151
Wilcox CS: *see* Cohn JB, 93
Williams JS: *see* Schentag JJ et al, 374
Wojciechowski NJ: *see* Skoutakis VA et al, 179
Wojciechowski NJ: *see* Skoutakis VA et al, 392

Y

Ylvisaker JT: *see* Porter JB et al, 381
Young B: *see* Rapp RP et al, 211

Z

Zander J: *see* Hunt-Fugate AK et al, 35
Zisook S: Commentary on buspirone, 331

A

AMA Drug Evaluations, fifth edition, review, 44
Acetaminophen, comparision with phenyltoloxamine in oral surgery pain, 216
Aerochamber, 109
Albuterol, pharmacology, chemistry, mechanism of action, 106; undesirable effects, 107; routes of administration, 108; pharmacokinetics, 109; use in emergency management of severely dyspneic asthmatic, 109; use for treatment of impending respiratory failure, 112; use in asthma requiring intermittent therapy, 113; comparison with other beta agonists given by metered-dose inhaler, 115; use in asthma requiring continuous treatment, 117
Alprazolam, use in bipolar-I depressions, 40; comparison with lorazepam and placebo, 93
Amoxapine, adverse reactions due to dopamine blockade, dystonia, oculogyric crisis, 35
Amoxicillin/potassium clavulanate, mechanism of action, pharmacokinetics, 123; in vitro susceptibilities, 124; in vivo effectiveness, 126; use in urinary tract infections, use in soft tissue infections, 127; use in respiratory tract infections, 128; use in venereal diseases, adverse effects, 129
Antiepileptic Drugs, second edition, review, 43
Applied Clinical Pharmacokinetics, review, 43
Arlix (Hoechst-Roussel), *see* piretanide, 170
Asendin (Lederle), *see* amoxapine, 35
Aspirin, versus diflunisal for rheumatoid arthritis, 151
Ativan (Wyeth), *see* lorazepam, 93
Augmentin (Beecham), *see* amoxicillin/potassium clavulanate, 122

B

Bentiromide, chemistry, clinical pharmacology, metabolism, testing procedure, 74; clinical use, 75; adverse effects, 78
Benzodiazepines, convulsions, 164
Bevantolol hydrochloride, selectivity in asthmatic patients, 205
Bupropion hydrochloride, chemistry, teratogenicity, mutagenicity, carcinogenicity, toxicology, 21; mechanism of action, 22; pharmacokinetics, 24; dosage and administration, clinical efficacy, 25; use in geriatric patients, children, patients who do not respond to tricyclic antidepressants and manic patients, 27; use in patients with schizophreniform disorders, adverse effects, effects on cardiac conduction, 28; drug interactions, plasma level monitoring, indications, 30
Buspar (Mead Johnson), *see* buspirone hydrochloride, 308
Buspirone hydrochloride, 308

C

Calcium-channel blocking agents, promising new uses, 137
Cefizox (Smith, Kline & French), *see* ceftizoxime, 47
Cefonicid, evaluation, 325
Cefotaxime, use in community-acquired penumonia in the elderly, 85
Ceftazidime, versus tobramycin/ticarcillin, 211; mechanisms of action, 47, antibacterial activity, beta-lactamase stability, 48; synergism with other antibiotics, pharmacokinetics, 50; adverse effects, clinical use, 53; use in pediatric patients, comparative studies, use as a prophylactic agent, 55
Chloramphenicol sodium succinate, use in community-acquired pneumonia in the elderly, 85
Chymex (Adria), *see* bentiromide, 74
Cimetidine, 381
Clindamycin phosphate, use in community-acquired pneumonia in the elderly, 85
Convulsions, benzodiazepine-related, 164

D

Diflunisal, versus aspirin for rheumatoid arthritis, 151
Digoxin toxicity, enhanced systemic elimination during oral activated charcoal therapy, 161
Diltiazem, promising new uses, 137; use in pulmonary hypertension, 138; use in Raynaud's disease, 139
Drugs and Drug Abuse, review, 44

E

Epipodophyllotoxins, 61
Erythromycin, use in community-acquired pneumonia in the elderly, 85
Etoposide, chemistry, formulation, pharmacology, pharmacokinetics, 62; clinical uses, 64; toxicity, 68; dosage and preparation, 69
Exirel (Pfizer), *see* pirbuterol hydrochloride, 1

F

Fendosal, 385
Fluphenazine decanoate, cholestatic jaundice and thrombocytopenia, 227

G

Gentamicin, effect of ticarcillin on gentamicin pharmacokinetics, 158

I

Indacrinone, 272, 278
Indomethacin, sustained release (Indos), 230
Indos (Merck Sharp & Dohme), *see* indomethacin, 230
Inhalaid, 109
Inspirease, 109

K

Ketoconazole, mechanism of action, 199; administration, distribution, metabolism, clinical efficacy, 200; adverse effects, 201; 343

L

Lorazepam, comparison with alprazolam and placebo, 93

M

Monocid (Smith Kline & French), *see* cefonicid, 325

N

NSC 141540, 62
Nafcillin, use in community-acquired pneumonia in the elderly, 85
Nifedipine, use in achalasia and esophageal spasm, 140; promising new uses, 137; use in hypertensive emergency, 137; use in pulmonary hypertension, 138; use in congestive heart failure, 139; use in aortic insufficiency, use in Raynaud's disease or phenomenon, 139; inhibitory effect on platelet function, 140; use in bypass surgery, 140; use in dysmenorrhea and preterm labor, use in asthma, use in hyperuricemia, 141; use in depression, 141
Nitrites, volatile, 284
Nizoral (Janssen), *see* ketoconazole, 199, 343
Norcuron (Organon), *see* vecuronium, 238

O

Oxacillin sodium, use in community-acquired pneumonia in the elderly, 85

P

Penicillin G, aqueous, use in community-acquired pneumonia in the elderly, 85
Pentoxifylline, 297
Percogesic (Richardson-Vicks), *see* acetaminophen, 216
Pharmacological and Chemical Synonyms, seventh edition, review, 46
Phenyltoloxamine, comparison with acetaminophen in oral surgery pain, 221
Pirbuterol hydrochloride, chemistry, metabolism, adverse effects, 2; pharmacodynamic properties, use in chronic obstructive pulmonary disease, 3; use in congestive heart failure, 5; subsensitivity, 6; dosage and administration, 7
Piretanide, chemistry, pharmacokinetics and metabolism, 170; animal pharmacology, 171; animal toxicology, human pharmacology, 172; use in congestive heart failure, 174; use in hypertension, 175; precautions and adverse effects, 176; dosage and administration, 177
Pneumonia, bacterial, pathogenesis, 81; bacterial, etiology, 82; bacterial, clinical presentation, differential diagnosis, laboratory and radiologic evaluation, 83; bacterial, therapy, 84; bacterial, prevention, 86
Podophyllotoxins, 61
Porphyria, acute intermittent, fundamental defect, 144; acute intermittent, diagnosis, clinical manifestations, pathology, 145; acute intermittent precipitating factors, management, 146; acute intermittent, unsafe and safe drugs, treatment of the acute attack, 147
Potassium chloride, 392
Procaine penicillin G, use in community-acquired pneumonia in the elderly, 85
Prolixin Decanoate, *see* fluphenazine decanoate, 227
Propantheline bromide, effects on absorption of oral ranitidine, 89
Proventil (Schering), *see* albuterol, 105

R

Ranitidine, effects of antacid and propantheline on absorption, 89
Rifampin, use in community-acquired pneumonia in the elderly, 85
Rotahaler, 109

S

Salbutamol, *see* albuterol, 105
Sufenta (Janssen), *see* sufentanil citrate, 11
Sufentanil citrate, chemistry, 11; distribution and elimination, animal toxicity, pharmacodynamics, 12; pharmacokinetics, 13; hypnosis and EEG effects, hemodynamic effects, 14; hormonal and metabolic effects, 16; adverse effects, 17
Sulfamethoxazole-trimethoprim, use in community-acquired pneumonia in the elderly, 85

T

Teniposide, 61
Theo-24 (Searle), *see* theophylline once daily, 181
Theo-dur (Key), *see* theophylline once daily, 181
Theophylline, once daily dosing, 181; dose dependency for absorption and elimination rates, 216; studies of bioavailability, 216
Ticarcillin, effect on gentamicin and tobramycin pharmacokinetics, 158
Ticarcillin/tobramycin, versus ceftazidime, 211
Tobramycin, effect of ticarcillin on tobramycin pharmacokinetics, 158
Tobramycin/ticarcillin, versus ceftazidime, 211
Trental (Hoechst-Roussel), *see* pentoxifylline, 297
Triamterene, renal stones, 100

U

USAN and the USP Dictionary of Drug Names, 1984 edition, review, 45
Uniphyl (Purdue Frederick), *see* theophylline once daily, 188
Uniphyllin (Mundipharma), *see* theophylline once daily, 188

V

VP 16, *see* etoposide, 61
VP 16-213, *see* etoposide, 61
Vancomycin hydrochloride, use in community-acquired pneumonia in the elderly, 85
Vecuronium, chemistry, 238; onset and duration of action, potency, 239; pharmacokinetics, 239; cardiovascular effects, 242
Ventolin (Glaxo), *see* albuterol, 105
Verapamil, promising new uses, 137; use in migraine headache, 139; inhibitory effect on platelet function, 140; use in Duchenne's muscular dystrophy, 140; use in mania, 141; use in oncologic conditions, 141
Vespid (Bristol), *see* etoposide, 61

W

Wellbutrin (Burroughs Wellcome), *see* bupropion hydrochloride, 20

X

Xanax (Upjohn), *see* alprazolam, 40, 93

Z

Zantac (Glaxo and Roche), *see* ranitidine, 89